Public Service Enterprise Group Inc
Change company Symbol lookup
Select an option...
PEG Public Service Enterprise Group Inc
LADR Ladder Capital Corp
NEMD iNeedMD Holdings Inc
CVS CVS Health Corp
CMI Cummins Inc
INVH Invitation Homes Inc
OII Oceaneering International Inc
SINO Sino-Global Shipping America Ltd
MLM Martin Marietta Materials Inc
KO Coca-Cola Co
Go

Utilities : Multi-Utilities | Large Cap Value
Company profile

Public Service Enterprise Group Incorporated (PSEG) is a holding company. The Company is an energy company with operations located primarily in the Northeastern and Mid-Atlantic United States. The Company's segments include Public Service Electric and Gas Company (PSE&G), PSEG Power LLC (Power) and Other. PSEG is engaged in the transmission of electricity and distribution of electricity and natural gas in certain areas of New Jersey. PSE&G is also the provider of last resort for gas and electric commodity service for end users in its service territory. Power is a multi-regional energy supply company that integrates the operations of its merchant nuclear and fossil generating assets with its power marketing businesses through energy sales in energy markets and fuel supply functions primarily in the Northeast and Mid-Atlantic United States through its principal subsidiaries. In addition, Power owns and operates solar generation in various states.

Closing Price
$58.15
Day's Change
-1.57 (-2.63%)
Bid
--
Ask
--
B/A Size
--
Day's High
59.72
Day's Low
57.43
Volume
(Heavy Day)
Volume:
3,240,554

10-day average volume:
2,148,714
3,240,554

Retinal Disease Therapeutics Market to Rise at 8.6% CAGR and Reach USD 21,318.0 Million by 2026, Facilitated by Increasing Regulatory Approvals for Favouring Drugs, says Fortune Business Insights

5:43 am ET September 16, 2020 (Globe Newswire) Print

The global retinal disease therapeutics market is likely to expand at an impressive rate driven by recent government participation towards prevention and control of retinal diseases. According to a report published by Fortune Business Insights, titled "Retinal Disease Therapeutics: Global Market Analysis, Insights, and Forecast, 2019-2026," the market is likely to reach US$ 21,318.0 Mn by the end of 2026. The market was valued at US$ 11,044.2 Mn in 2018 and is likely to witness a CAGR of 8.6% in the forecast period.

Highlights of the Report:

-- Analysis of the impact of Covid-19 that the market would face in the near future.

-- In-depth analysis of the growth drivers and obstacles.

-- Profile of all the companies operating in the market.

-- Elaborate data about the dominating region.

-- Competitive landscape consisting of mergers & acquisitions, investments, partnerships, new product launches, opening of new facilities, and new contracts.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/retinal-disease-therapeutics-market-100311

F. Hoffmann-La Roche AG's 'Lucentis' is Gaining Increasing Popularity

The global retinal disease therapeutics market is consolidated in nature, with only a handful of market players accounting for maximum share of the market. With consolidation, it is becoming increasingly difficult for newer market entrants to establish a stronghold or derive immediate success.

Therefore, the global market is boosted by products and concepts introduced by existing companies. One such instance of this development is the "Lucentis" therapy, put forward by F. Hoffmann-La Roche AG. Lucentis was introduced with an aim of providing therapeutic advice and development of products for patients suffering from chronic disease. In 2017, the Food and Drug Administration (FDA) approved Lucentis for diabetic retinopathy. The diabetic retinopathy is a severe kind of disorder that has accounted for majority of cases of blindness in the US.

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

To get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/retinal-disease-therapeutics-market-100311

Lucentis was an instant hit among healthcare professionals, after it was backed by a series of clinical trials and aprovals from the National Institute of Health (NIH). Excellent clinical effects of Lucentis have led to a subsequent rise in demand for the medicine among patients. The increasing demand has contributed to the growth of the global retinal disease therapeutics market and is likely to favor the market in the forthcoming years.

North America to Emerge Dominant in the Forecast Period

The increasing government investment towards research and development of retinal disease drugs and diagnostic devices is enabling growth in the retinal diseases therapeutics market in North America. North America has emerged dominant in the global retinal disease therapeutics market in recent years.

The retinal disease therapeutics market in North America was valued at US$ 4056.5Mn in 2018 and is likely to increase in the coming years. Improved health infrastructures, increasing patient pool, and favourable health reimbursement policies are some of the factors that are likely to boost the regional market in the forthcoming years. High prevalence of retinal diseases in Asia Pacific is a major reason, why this region is estimated to rise with the highest CAGR in the forecast period.

Quick Buy - Retinal Disease Therapeutics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100311

List of the leading companies that are operating in the global retinal disease therapeutics market:

-- Merck & Co., Inc.

-- Novartis AG

-- Allergan plc

-- F. Hoffmann-La Roche AG

-- Regeneron Pharmaceuticals, Inc.

-- Santen Pharmaceutical Co., Ltd.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/retinal-disease-therapeutics-market-100311

Retinal Disease Therapeutics Market Segmentations:

By Disease Indication

? Macular Degeneration

? Diabetic Retinopathy

? Diabetic Macular Edema

? Retinal Vein Occlusion

? Others

By Distribution Channel

? Hospital Pharmacy

? Retail Pharmacy

? Others

By Geography

? North America (USA and Canada)

? Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

? Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

? Latin America (Brazil, Mexico, Rest of Latin America)

? Middle East & Africa (GCC, South Africa, Rest of Middle East & Africa)

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/retinal-disease-therapeutics-market-100311

Have a Look at Related Reports:

Glaucoma Therapeutics Market Share and Global Trend By Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Combination Drugs), By Disease Indication (Open Angle Glaucoma, Angle Closure Glaucoma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026

Ophthalmic Disease Therapeutics Market Share and Global Trend By Disease Indication (Glaucoma, Retinal Diseases, Dry Eye Disease, Allergy & Infections), By Drug Class (Anti-inflammatory, Anti-infectives, Anti-VEGF, Anti-glaucoma), By Dosage Form (Solid, Liquid, Semi-solid), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) By Geography Forecast till 2026

Ophthalmic Lasers Market Share and Global Trend By Type (Excimer Lasers, Femtosecond Lasers, Nd Yag Lasers, Diode Lasers), Technology (Photodisruption, Selective Laser Trabeculoplasty, Photocoagulation), Application (Cataract Treatment, Glaucoma Treatment, Refractive Errors Treatment), End-User (Ophthalmic Laser Centers,Hospitals ) & Geography Forecast till 2026

Antipsychotic Drugs Market Share and Industry Analysis, By Disease (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Others), By Therapeutic Class (First Generation, Second Generation, Third Generation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019 - 2026

Europe Compression Bandages Market Share & Industry Analysis, By Product (Short Stretch Bandages, Long Stretch Bandages, Multilayer Compression Bandages), By Material (Polyster, Latex, Cotton, Others), By Application (Wound Management, Deep Vein Thrombosis, Lymphedema, Others), By End-user (Hospitals & Ambulatory Surgical Centers, Clinics, Nursing Care Centers & Skilled Nursing Facilities, Home Care, Others) and Regional Forecast, 2019 - 2026

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights(TM) Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Fortune Business Insights(TM)

LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/retinal-disease-therapeutics-market-9100

https://ml.globenewswire.com/media/05408ba1-26b1-4fdd-8f48-1af4df373348/small/fbi-logo-tm-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.